Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
2.030
-0.010 (-0.49%)
At close: Nov 1, 2024, 4:00 PM
2.040
+0.010 (0.49%)
After-hours: Nov 1, 2024, 6:10 PM EDT
Esperion Therapeutics Employees
Esperion Therapeutics had 240 employees as of December 31, 2023. The number of employees increased by 41 or 20.60% compared to the previous year.
Employees
240
Change (1Y)
41
Growth (1Y)
20.60%
Revenue / Employee
$1,157,450
Profits / Employee
-$410,404
Market Cap
398.34M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Cross Country Healthcare | 13,131 |
ZimVie | 2,600 |
GRAIL | 1,360 |
Butterfly Network | 225 |
4D Molecular Therapeutics | 147 |
MaxCyte | 143 |
Foghorn Therapeutics | 116 |
Theravance Biopharma | 99 |
ESPR News
- 8 days ago - Esperion to Report Third Quarter 2024 Financial Results on November 7 - GlobeNewsWire
- 5 weeks ago - Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) - GlobeNewsWire
- 2 months ago - Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs - Seeking Alpha
- 2 months ago - Esperion Therapeutics: Strategically Positioned To Grow - Seeking Alpha
- 2 months ago - Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update - GlobeNewsWire